ClinicalTrials.gg
CompletedNCT03796858COSMOSUpdated Feb 3, 2025

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy

A Phase 3 interventional study of Guselkumab 100 mg and Placebo in Arthritis, Psoriatic, sponsored by Janssen Pharmaceutica N.V., Belgium. Completed at 117 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.

Enrollment
6th of 14
285 · median 173
Started
2019
the only one that year
Phase 3
7 of 14
1 open now
Registered
4th of 14
by date
Lead sponsor
1 of 14
Janssen Pharmaceutica N.V., Belgium

Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 3, and was the 4th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing guselkumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the reduction in signs and symptoms of joint disease.

Read the detailed description

Psoriatic arthritis is a multi-faceted disease that impacts the joints, soft tissues, and skin, all of which not only results in functional disability and impaired quality of life, but participants with this disease also have increased mortality. Guselkumab is a monoclonal antibody that binds to human interleukin 23 (IL-23) and inhibits IL-23 specific intracellular signaling and subsequent activation and cytokine production. Investigation of guselkumab in this Phase 3b PsA clinical study is supported by the favorable efficacy and safety results from Phase 2 study of guselkumab in PsA and Phase 2 and Phase 3 studies in psoriasis including the subset of participants with PsA. The primary hypothesis is that guselkumab 100 milligram (mg) at Weeks 0, 4, and every 8 weeks (q8w) thereafter is superior to placebo which will be assessed by the proportion of participants achieving an American College of Rheumatology (ACR 20) response at Week 24. The study includes 2 periods: A 24-week double-blind, placebo-controlled period for the primary analysis of the efficacy and safety of guselkumab, compared with placebo and a 32-week active-treatment and safety follow-up period for additional analysis of the efficacy and safety of guselkumab. Safety will be monitored throughout the study (Up to Week 56).

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening
  • Have active PsA as defined by at least 3 swollen joints and at least 3 tender joints at screening and at baseline
  • Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
  • Have an inadequate response to anti-TNF alpha therapy, defined as presence of active PsA despite previous treatment with either 1 or 2 anti-TNF alpha agents and either of the following: a) Lack of benefit of an anti-TNF alpha therapy, as documented in the participant history by the treating physician, after at least 12 weeks of etanercept, adalimumab, golimumab, or certolizumab pegol therapy (or biosimilars) and/or at least a 14-week dosage regimen (i.e., at least 4 doses) of infliximab (or biosimilars). Documented lack of benefit may include inadequate improvement in joint counts, skin response, physical function, or disease activity, b) Intolerance to an anti-TNF alpha therapy, as documented in the patient history by the treating physician, to etanercept, adalimumab, golimumab, certolizumab pegol, or infliximab (or biosimilars, if available)
  • Be willing to refrain from the use of complementary therapies for PsA or psoriasis including ayurvedic medicine, traditional Taiwanese, Korean, or Chinese medications and acupuncture within 2 weeks before the first study intervention administration and through Week 48

Exclusion criteria

Exclusion Criteria:

  • Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease
  • Has ever received more than 2 different anti-TNF alpha agents
  • Has previously received any biologic treatment (other than anti-TNF Alpha agents), including, but not limited to ustekinumab, abatacept, secukinumab, tildrakizumab, ixekizumab, brodalumab, risankizumab, or other investigative biologic treatment
  • Has previously received tofacitinib, baricitinib, filgotinib, peficitinib (ASP015K), decernotinib (VX 509), or any other a Janus kinase (JAK) inhibitor
  • Has previously received any systemic (for example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab

    Participants will receive guselkumab 100 milligram (mg) Subcutaneous (SC) injection at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo SC at Week 24 to maintain the blind. At Week 16, Participants who meet the early escape criteria will receive placebo at Week 16 and guselkumab at Week 20, then guselkumab every 8 weeks (q8w).

    Drug: Guselkumab 100 mg · Drug: Placebo

  • Experimental
    Group 2: Placebo followed by Guselkumab

    Participants will receive placebo SC injection at Weeks 0, 4, 12, and 20, and will crossover to receive guselkumab 100 mg SC injection at Weeks 24, 28, 36, and 44. At Week 16, Participants who meet the early escape criteria will receive guselkumab at Weeks 16 and 20, then guselkumab q8w.

    Drug: Guselkumab 100 mg · Drug: Placebo

Interventions

  • Participants will receive guselkumab 100mg as SC injection.

    Also known as: CNTO 1959

  • DrugPlacebo

    Participants will receive placebo as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve an American College of Rheumatology (ACR) 20 Response at Week 24

    The ACR 20 Response is defined as greater than or equal to (\>=) 20 percent (%) improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20 percent improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP).

    Time frame: Week 24

Secondary outcomes

  1. Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24

    The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and activities of daily living). Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area). Overall score is computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline, Week 24

  2. Percentage of Participants who Achieve an ACR 50 Response at Week 24

    The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=50 percent improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP).

    Time frame: Week 24

  3. Change from Baseline in 36-Item Short form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

    The SF-36 is a generic health survey with 36 items that measure functional health and well-being from the participant's perspective. The survey is summarized into 8 dimensions/scales: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH). The physical component summary measure is derived from 4 of the 8 health dimensions (aggregate of PF, RP, BP, and GH scales). The minimum score is 0 and the maximum score is 100. A higher score indicates a better health state.

    Time frame: Baseline, Week 24

  4. Percentage of Participants who Achieve Psoriatic Area and Severity Index (PASI) 100 Response at Week 24 Among Participants with >=3% body Surface area Psoriatic Involvement and an Investigator's Global Assessment (IGA) Score of >=2 (Mild) at Baseline

    PASI 100 response is defined as 100% improvement in PASI score from baseline (PASI score of 0). The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI scoring system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

    Time frame: Week 24

07

Study locations

117 sites
  • CHU Saint Pierre BXL
    Brussels, 1000, Belgium
  • Reuma Clinic
    Genk, 3600, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Diagnostic - Consulting Center II-Pleven
    Pleven, 5800, Bulgaria
  • Medical Center Medconsult-Pleven
    Pleven, 5800, Bulgaria
  • Multiprofile Hospital for Active Treatment Plovdiv
    Plovdiv, 4003, Bulgaria
  • Multiprofile Hosptal for Active Treatment Eurohospital Plovdiv
    Plovdiv, 4004, Bulgaria
  • Medical Center Teodora
    Ruse, 7003, Bulgaria
  • Diagnostic Consulting Center No 17
    Sofia, 1505, Bulgaria
  • Military Medical Academy
    Sofia, 1606, Bulgaria
  • Hopital Pellegrin Tripode - CHU de Bordeaux
    Bordeaux, 33076, France
  • CHU Lapeyronie
    Montpellier, 34295, France
  • Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
    Orleans, 45067, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Hôpital Pitié-Salpétrière
    Paris, 75013, France
  • Hopital Cochin
    Paris, 75014, France
  • Centre Hospitalier Universitaire de Toulouse - Hopital Purpan
    Toulouse, 30159, France
  • CHU Trousseau - Service de Rhumatologie
    Tours, 37044, France
  • Universitatsklinikum Dusseldorf
    Dusseldorf, 40225, Germany
  • Hamburger Rheuma Forschungszentrum II
    Hamburg, 20095, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, 44649, Germany
  • Rheumatologische Schwerpunktpraxis
    Rendsburg, 24768, Germany
  • Krankenhaus St. Josef
    Wuppertal, 42105, Germany
  • 424 Military Hospital of Thessaloniki
    Thessaloniki, 56429, Greece
  • Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
    Budapest, 1023, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz
    Gyula, 5700, Hungary
  • Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
    Nyiregyhaza, 4400, Hungary
  • MAV Korhaz es Rendelointezet
    Szolnok, 5000, Hungary
  • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
    Székesfehérvár, 8000, Hungary
  • Vital Medical Center Orvosi es Fogaszati Kozpont
    Veszprem, 8200, Hungary
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Bnai Zion Medical Center
    Hifa, 31048, Israel
  • Carmel Medical Center
    Hifa, 34362, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, 80131, Italy
  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
    Palermo, 90127, Italy
  • Policlinico Tor Vergata
    Roma, 00133, Italy
  • Complesso Integrato Columbus
    Rome, 00168, Italy
  • Humanitas Hospital
    Rozzano (MI), 20089, Italy
  • Szpital Uniwersytecki Nr 2 w Bydgoszczy
    Bydgoszcz, 85 168, Poland
  • Centrum Kliniczno Badawcze
    Elblag, 82-300, Poland
  • Dermed Centrum Medyczne Sp z o o
    Lodz, 90 265, Poland
  • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
    Lodz, 90-242, Poland
  • NZOZ Lecznica MAK MED S C
    Nadarzyn, 05 830, Poland
  • Medycyna Kliniczna
    Warsaw, 00-874, Poland
  • Mazowieckie Centrum Reumatologii i Osteoporozy
    Warszawa, 04-030, Poland
  • WroMedica I Bielicka A Strzalkowska s c
    Wroclaw, 51 685, Poland
  • Uls Almada Seixal - Hosp. Garcia de Orta
    Almada, 2805 267, Portugal
  • Uls Regiao Aveiro - Hosp. Infante D. Pedro
    Aveiro, 3814-501, Portugal
  • Uls Braga - Hosp. Braga
    Braga, 4710 243, Portugal
  • Ipr Inst Port de Reumatologia
    Lisboa, 1050 034, Portugal
  • Uls Lisboa Ocidental - Hosp. Egas Moniz
    Lisboa, 1349 019, Portugal
  • Uls Santa Maria - Hosp. Santa Maria
    Lisboa, 1649 035, Portugal
  • Ulsam - Hosp. Conde de Bertiandos
    Ponte de Lima, 4990-041, Portugal
  • Chelyabinck Regional Clinical Hospital
    Chelyabinsk, 454076, Russian Federation
  • Kemerovo State Medical University
    Kemerovo, 650000, Russian Federation
  • Medical Centre Maximum Health
    Kemerovo, 650066, Russian Federation
  • Family polyclinic #4
    Korolev, 141060, Russian Federation
  • Krasnodar Clinical Dermatovenerologic Dispensary
    Krasnodar, 350020, Russian Federation
  • Krasnoyarsk State Medical University
    Krasnoyarsk, 660022, Russian Federation
  • Orenburg State Medical Academy
    Orenburg, 460000, Russian Federation
  • Rostov Regional Clinical Dermatovenerological Dispensary
    Rostov, 344007, Russian Federation
  • Ryazan Regional Clinical Dermatovenerological Dispensary
    Ryazan, 390046, Russian Federation
  • Samara Regional Clinical Hospital Named After V.D.Seredavin
    Samara, 443095, Russian Federation
  • Sararov Regional Clinical Hospital
    Saratov, 410053, Russian Federation
  • Smolensk regional hospital on Smolensk railway station
    Smolensk, 214025, Russian Federation
  • Leningrad region clinical hospital
    St-Petersburg, 194291, Russian Federation
  • Tula Regional Clinical Dermatovenerological Dispensary
    Tula, 300053, Russian Federation
  • Republican Clinical Hospital - G.G. Kuvatov
    Ufa, 450005, Russian Federation
  • Ulyanovsk Regional Clinical Hospital
    Ulyanovsk, 432063, Russian Federation
  • Regional Clinical Hospital
    Velikiy Novgorod, 173008, Russian Federation
  • Clinical Emergency Hospital n.a. N.V. Solovyev
    Yaroslavl, 150003, Russian Federation
  • Clinical Hospital #3
    Yaroslavl, 150007, Russian Federation
  • Hosp Univ A Coruna
    A Coruna, 15006, Spain
  • Hosp. Univ. de Cruces
    Barakaldo, 48902, Spain
  • Hosp. Univ. Germans Trias I Pujol
    Barcelona, 08916, Spain
  • Hosp. Univ. de Basurto
    Bilbao, 48013, Spain
  • Hosp Reina Sofia
    Cordoba, 14004, Spain
  • Hosp. Univ. Ramon Y Cajal
    Madrid, 28034, Spain
  • Hosp. Univ. 12 de Octubre
    Madrid, 28041, Spain
  • Hosp. Univ. de Getafe
    Madrid, 28905, Spain
  • Hosp Regional Univ de Malaga
    Málaga, 29009, Spain
  • Hosp. Clinico Univ. de Santiago
    Santiago de Compostela, 15706, Spain
  • Hosp. Virgen Macarena
    Sevilla, 41009, Spain
  • Hosp. Infanta Luisa
    Sevilla, 41010, Spain
  • Hosp. Virgen Del Rocio
    Sevilla, 41013, Spain
  • Hosp. Ntra. Sra. de Valme
    Sevilla, 41014, Spain
  • Hosp. Do Meixoeiro
    Vigo, 36312, Spain
  • Communal Noncommercial Enterprise Cherkasy Regional Hospital of Cherkasy Regional Council
    Cherkasy, 18009, Ukraine
  • Ivano-Frankivsk National Medical University, Ivano-Frankivsk City Clinical Hospital
    Ivano-Frankivsk, 76018, Ukraine
  • City Multifield Hospital #18, Mechnikov Institute of Microbiology and Immunology of NAMS
    Kharkiv, 61029, Ukraine
  • Municipal non-commercial enterprise of Kharkiv Regional Council Regional Clinical Hospital
    Kharkiv, 61058, Ukraine
  • Khmelnitckiy regional hospital
    Khmelnytsky, 29000, Ukraine
  • Kyiv City Clinical Hospital #3, National Medical University
    Kyiv, 02125, Ukraine
  • Medical Center 'Consylium Medical'
    Kyiv, 04050, Ukraine
  • Kyiv Railway Station Clinical Hospital #2
    Kyiv, Ukraine

Showing the first 100 of 117 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, Noel W, Schett G, McInnes IB. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022 Mar;81(3):359-369. doi: 10.1136/annrheumdis-2021-220991. Epub 2021 Nov 24. PubMed 34819273 ↗

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Nov 2020, 19 months.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 19 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2019
First posted
Jan 8, 2019
StartActual
Mar 22, 2019
Primary completionActual
Nov 11, 2020
CompletionActual
Nov 11, 2020
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03796858
Responsible party
Sponsor
First posted
Jan 8, 2019
Start date
Mar 22, 2019
Primary completion
Nov 11, 2020
Completion
Nov 11, 2020
Last update
Feb 3, 2025

Study contacts

Janssen Pharmaceutica N.V., Belgium Clinical Trial
study director · Janssen Pharmaceutica N.V., Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion